Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Gli effetti della terapia con ferro endovenoso a basso dosaggio rispetto a quella ad alto dosaggio con derisomaltosio ferrico in pazienti con insufficienza cardiaca cronica e carenza di ferro (IRONDOSE)

4 novembre 2026 aggiornato da: Jingyi Ren, China-Japan Friendship Hospital

Gli effetti della terapia con ferro endovenoso a basse dosi rispetto ad alte dosi con derisomaltosio ferrico in pazienti con insufficienza cardiaca cronica e carenza di ferro: uno studio randomizzato, in aperto, con endpoint cieco (IRONDOSE)

This study will address whether intravenous (IV) iron repletion with a more intensive target will provide greater benefits in improving exercise capacity for patients with chronic heart failure and iron deficiency. One group of participants will receive a high-dose IV iron regimen with a more intensive target, and the other group will receive a low-dose IV iron regimen with a less intensive target.

Panoramica dello studio

Descrizione dettagliata

Iron deficiency is a common and important comorbidity in heart failure. Randomized controlled trials have consistently demonstrated a beneficial effect of IV iron on exercise capacity and quality of life in iron-deficient patients with HF and reduced ejection fraction. However, these randomized controlled trials exhibit striking heterogeneity in targeting levels for maintenance strategies of IV iron repletion. Some studies (FERRIC-HF, FAIR-HF) withheld intravenous iron in cases of ferritin >800 ng/mL, hemoglobin >16.0 g/dL, or transferrin saturation (TSAT) >50%, while other studies (HEART-FID, IRONMAN) focused on targeting levels that are simply above the definition of iron deficiency. Additionally, the PIVOTAL trial showed that high-dose IV iron decreased recurrent heart failure events in patients undergoing hemodialysis compared to a lower-dose regimen. Whether functional outcomes differ between those on lower versus higher iron repletion targets among patients with heart failure remains unknown. This study will help us address this question.

This is an investigator-initiated, prospective, randomized, open-label blind endpoint study to assess the effects of high-dose IV iron repletion compared to a low-dose IV iron repletion on 12-month change in peak oxygen uptake (VO2) for patients with chronic heart failure and concomitant iron deficiency.

Patients with chronic heart failure and iron deficiency will be enrolled and randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during the follow-up period. In the high dose group, iron dosing will repeat as long as the serum ferritin was not >700ng/mL, or if TSAT was not >40%. Patients in the low dose group will receive repeat iron dosing if ferritin <100 ng/mL, or if ferritin 100-300 ng/mL and TSAT <20%, in line with criteria for iron deficiency in current guidelines.

Tipo di studio

Interventistico

Iscrizione (Stimato)

114

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina, 100044
        • Reclutamento
        • China-Japan Friendship Hospital
        • Investigatore principale:
          • Jingyi Ren
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Age >18 years.
  2. Left ventricular ejection fraction (LVEF) <50% within 2 years prior to planned randomization (assessed by echocardiography or MRI).
  3. New York Heart Association (NYHA) class II ~ III.
  4. Either hospitalization for HF within 6 months prior to planned randomization or elevated plasma levels of natriuretic peptides within 3 months of randomization. a. For patients in sinus rhythm: NT- proBNP >300 pg/mL or BNP >100 pg/mL. b. For patients in atrial fibrillation: NT-proBNP >600 pg/mL or BNP >200 pg/mL.
  5. Subjects with stable CHF (NYHA II/III functional class) on optimal background therapy (as determined by the investigator) for at least 4 weeks with no dose changes of heart failure drugs during the last 2 weeks (with the exception of diuretics).
  6. Serum ferritin <100 ng/mL or serum ferritin 100-300 ng/mL and TSAT <20%.
  7. Able and willing to perform a CPET at the time of randomization.
  8. Able and willing to provide informed consent.

Exclusion Criteria:

  1. Hemoglobin <9.0 g/dL or Hemoglobin >15.0 g/dL.
  2. Renal dialysis or MDRD/CKD-EPI estimated glomerular filtration rate (eGFR) <15 ml/min/1.73m2.
  3. Body weight <35 kg.
  4. Heart failure was secondary to valvular diseases or congenital heart diseases.
  5. History of acquired iron overload; known hemochromatosis or first relatives with hemochromatosis.
  6. Known hypersensitivity to ferric derisomaltose or other IV iron product.
  7. Known active infection (defined as currently treated with oral or intravenous antibiotics), bleeding (gastrointestinal hemorrhagia, menorrhagia, history of peptic ulcer with no evidence of healing or inflammatory bowel disease), malignancy, and hemolytic anemia.
  8. History of chronic liver disease and/or alanine transaminase (ALT) or aspartate transaminase (AST) >3 times the upper limit of the normal range; myelodysplastic disorder; and known HIV/AIDS disease.
  9. Acute myocardial infarction, acute coronary syndrome, transient ischemic attack, or stroke within 3 months prior to randomization.
  10. Revascularization therapy (coronary artery bypass grafting, percutaneous intervention, or major surgery) within 3 months prior to randomization; or planning cardiac surgery or revascularization.
  11. Already receiving erythropoietin, IV or oral iron therapy, and blood transfusion in previous 30 days prior to randomization.
  12. Use of concurrent immunosuppressive therapy
  13. Any of the following diseases that hinders exercise testing: severe musculoskeletal disease, unstable angina, obstructive cardiomyopathy, severe uncorrected valvular disease, or uncontrolled slow or rapid arrhythmia (mean ventricular rate >100 beats/min at rest), or uncontrolled hypertension with blood pressure >160/100 mm Hg.
  14. Investigator considers a possible alternative diagnosis to account for the patient's HF symptoms: severe obesity, primary pulmonary hypertension, or chronic obstructive pulmonary disease.
  15. Pregnancy or breast feeding.
  16. Participation in another intervention study involving a drug or device within the past 90 days.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: High dose

Participants randomized to this arm will receive repeat iron dosing as long as the serum ferritin was not >700 ng/mL, or if TSAT was not >40% during follow-up.

Iron to be administered as ferric derisomaltose. Ferric derisomaltose will be administered according to the dosing schedule determined by the patient's body weight and hemoglobin value.

Infused over a minimum of 15 mins for doses up to and including 1000mg, and a minimum of 30 mins for doses >1000mg.

After baseline assessment, participants will be randomized in a 1:1 ratio to receive a high-dose IV iron regimen and a low-dose IV iron regimen. After the initial iron repletion, ferritin concentration and TSAT were measured every three months and the results used to determine the dose of ferric derisomaltose during follow-up.

In the high-dose group, participants will receive repeat iron dosing as long as the serum ferritin was not >700 ng/mL, or if TSAT was not >40% during follow-up.

Altri nomi:
  • Obiettivo più intensivo
Comparatore attivo: Low dose

Participants randomized to this arm will receive repeat iron dosing if ferritin <100 ng/mL or if ferritin 100-300 ng/mL and TSAT <20% during follow-up.

Iron to be administered as ferric derisomaltose in analogy to high-dose arm.

In the low-dose group, participants will receive repeat iron dosing if ferritin <100 ng/mL or if ferritin 100-300 ng/mL and TSAT >20% during follow-up.

Altri nomi:
  • Obiettivo meno intensivo

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Change in peak VO2 (ml/min/kg)
Lasso di tempo: Baseline to Week 52

Peak VO2 measured by a maximal effort Cardiopulmonary Exercise Test (CPET)

Baseline to Week 52

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Variazione della distanza a piedi in 6 minuti (m)
Lasso di tempo: Riferimento alla settimana 26 e alla settimana 52
Riferimento alla settimana 26 e alla settimana 52
Change in VO2 at ventilatory threshold (ml/min)
Lasso di tempo: Baseline to Week 52

Measured by CPET

Baseline to Week 52
Change in heart rate at peak exercise (bpm)
Lasso di tempo: Baseline to Week 52

Measured by CPET

Baseline to Week 52
Change in peak respiratory exchange ratio
Lasso di tempo: Baseline to Week 52

Measured by CPET

Baseline to Week 52
Change in myocardial iron content by cardiac magnetic resonance imaging T2 star
Lasso di tempo: Baseline to Week 52

Measured by cardiac magnetic resonance imaging

Baseline to Week 52
Change in skeletal muscle iron content by magnetic resonance imaging T2 star
Lasso di tempo: Baseline to Week 52

Measured by skeletal muscle magnetic resonance imaging

Baseline to Week 52
Change in the clinical summary score by Kansas City Cardiomyopathy Questionnaire (KCCQ)
Lasso di tempo: Baseline to Week 52

The KCCQ is a validated instrument for self-assessment of quality of life and health status in heart failure patients. The clinical summary score, which is derived from the physical limitations and heart failure symptoms domains of the KCCQ is a valid measure for assessing the patient's health aspects that may be influenced by CV medications. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

Baseline to Week 52
Change in the EQ-5D-5L questionnaire indexed value
Lasso di tempo: Baseline to Week 52

EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).

Baseline to Week 52
Change in cognitive function score by Mini-Mental State Examination (MMSE)
Lasso di tempo: Baseline to Week 52

The MMSE is a cognitive test. The score is ranged from 0-30 (units of a scale). 30 points is the better outcome. The investigators will assess the change in the score.

Baseline to Week 52
Change in concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP, pg/mL)
Lasso di tempo: Baseline to Week 52

Tested in blood samples

Baseline to Week 52
Change in left ventricular ejection fraction (LVEF, %)
Lasso di tempo: Baseline to Week 52

Assessed by echocardiography

Baseline to Week 52
Change in left ventricular global longitudinal stress (LVGLS, %)
Lasso di tempo: Baseline to Week 52

Assessed by echocardiography

Baseline to Week 52
Mortality and heart failure-related hospitalization rates
Lasso di tempo: Up to 52 weeks

Effects on mortality and HF-related hospitalization rates in patients with heart failure.

Up to 52 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 ottobre 2023

Completamento primario (Stimato)

1 agosto 2027

Completamento dello studio (Stimato)

1 agosto 2027

Date di iscrizione allo studio

Primo inviato

19 maggio 2024

Primo inviato che soddisfa i criteri di controllo qualità

19 maggio 2024

Primo Inserito (Effettivo)

23 maggio 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

5 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi